Journal profile · Hematology
LEUKEMIA & LYMPHOMA
ISSN 1042-8194 · eISSN 1029-2403 · Informa Healthcare · ENGLAND · Monthly · Founded 1989
LEUKEMIA & LYMPHOMA: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.11; hybrid open access; median 95 days to acceptance (103 articles, last 24 months); community-reported acceptance: about 66.66%; 349 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
LEUKEMIA & LYMPHOMA is published by Informa Healthcare and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and Acute Myeloid Leukemia Research, together about 41.8% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
Source: LetPub
Research area (LetPub): Hematology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lymphoma Diagnosis and TreatmentMedicine17.7%
- Chronic Lymphocytic Leukemia ResearchMedicine13.3%
- Acute Myeloid Leukemia ResearchMedicine10.8%
- Acute Lymphoblastic Leukemia researchMedicine6.4%
- Viral-associated cancers and disordersMedicine5.9%
- Chronic Myeloid Leukemia TreatmentsMedicine5.7%
- Multiple Myeloma Research and TreatmentsMedicine4.7%
- Hematopoietic Stem Cell TransplantationMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.11LetPub ·
- CiteScore 2026-06
- 3.9LetPub ·
- SJR 2026-06
- 0.86LetPub ·
- SNIP 2026-06
- 0.68LetPub ·
- h-index
- 82LetPub ·
- h-index
- 118OpenAlex ·
- i10-index
- 7,053OpenAlex ·
- 2-year mean citedness
- 1.73OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 12.17%LetPub ·
Volume
- Articles per year
- 214LetPub ·
Articles by year OpenAlex count · 14,296 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 233 | 50 | 58 |
| 2025 | 349 | 73 | 428 |
| 2024 | 334 | 101 | 1,098 |
| 2023 | 285 | 82 | 1,251 |
| 2022 | 414 | 114 | 2,611 |
| 2021 | 465 | 121 | 4,018 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
95 daysMedian, submission to acceptance · P25–P75 69 days – 116 days
- Acceptance to online
- median 14 days (103 articles)
- Submission to online
- median 110 days
- Sample
- 103 articles with submission and acceptance dates (685 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1.8 monthsLetPub ·
- Average acceptance (community reports)
- 66.66%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1989
- ISSN
- 1042-8194
- Electronic ISSN
- 1029-2403
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about LEUKEMIA & LYMPHOMA
What CAS zone is LEUKEMIA & LYMPHOMA in?
In the 2025 upgraded edition of the CAS Journal Ranking, LEUKEMIA & LYMPHOMA is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology / Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of LEUKEMIA & LYMPHOMA?
The latest impact factor listed by LetPub is 2.11; CiteScore 3.9, h-index 118.
How long does peer review take at LEUKEMIA & LYMPHOMA?
Based on the dates recorded on 103 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 95 days (interquartile range 69–116 days); authors report an average review time of about 1.8 months; the community-reported acceptance is “about 66.66%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index LEUKEMIA & LYMPHOMA?
According to LetPub and DOAJ records, LEUKEMIA & LYMPHOMA is indexed in SCIE and Scopus.
Is LEUKEMIA & LYMPHOMA open access, and what is the APC?
LEUKEMIA & LYMPHOMA is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .